[Current status and future perspective of CAR T-cell therapy for acute myeloid leukemia]

For over a decade, various chimeric antigen receptor (CAR)-modified T-cells targeting myeloid antigens have been researched and developed overseas for relapsed/refractory acute myeloid leukemia (AML). However, none of them is domestically and internationally nearing approval. Clinical trial results on CAR T-cells targeting LeY, CD33, NKG2D ligands, CD38, or CD123 have been reported; however, they have not shown significant clinical benefit. More recently, several promising studies in CLL1 CAR T-cells have been reported in China, which attracted attention. We started a first-in-human clinical trial of GMR CAR T-cells in patients with CD116-positive myeloid neoplasms, particularly AML and juvenile myelomonocytic leukemia, in 2021. CAR T-cells can be a promising and practical treatment option for patients with relapsed/refractory AML.